ImmunoPrecise Antibodies (IPA) said Monday that it has made a 'significant contribution' to an anti-aging study led by scientists at the Mayo Clinic.
The biotech firm said the study used its proprietary rabbit B Cell Select platform to isolate and generate antibodies that target phosphorylated ubiquitin, which is an indicator of mitochondrial damage.
"This study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's," the company said.
Price: 0.6497, Change: -0.03, Percent Change: -4.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments